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COST OF TREATMENT OF 
HYPERCHOLESTEROLAEMIA TO NHF GOALS
IN AUSTRALIA
Wlodarczyk J1, Barter PJ2, O’Brien R3, Talmont D4, Ortiz M4
1John Wlodarczyk Consulting Services, Newcastle, NSW, 
Australia; 2Royal Adelaide Hospital, Adelaide, Australia; 
3Monash Medical Centre, Melbourne, Australia; 4Pfizer Pty Ltd, 
Sydney, Australia
OBJECTIVE: To estimate the comparative cost-effective-
ness of atorvastatin and simvastatin. METHODS: A ran-
domized clinical trial set in general practice. Effectiveness
was measured by percentage reduction in total choles-
terol and percentage of patients achieving NHF targets.
The costs calculated in the study were hospital admis-
sions, emergency room/clinic visits, visits to GPs and spe-
cialists, tests/investigations, treatment of adverse events
and drug costs. RESULTS: Of the 691 patients in the
atorvastatin arm, 682 used health care resources. Of the
337 patients in the simvastatin arm, 332 used health care
resources. The monthly drug costs with atorvastatin was
$48.30 for 10mg, $66.93 for 20mg, with simvastatin at
$42.06 for 10 mg, $58.12 for 20mg. The average cost of
health care for atorvastatin and simvastatin was $460.48
and $490.11 respectively (p  0.47). Adverse events ac-
counted for 60% of all health care costs in the atorvasta-
tin group, 77% in the simvastatin group. The weighted
average monthly drug costs (WAMDC) after 6 weeks of
treatment were $48.30 for atorvastatin and $42.06 for
simvastatin. 38% of patients reached NHF target choles-
terol levels on atorvastatin, 25.5% on simvastatin. The
cost per responder was $1.27 with atorvastatin, $1.63
with simvastatin. After 12 weeks of treatment the
WAMDC was $59.53 for atorvastatin, $53.77 for sim-
vastatin with 47.5% and 33.8% response rates, respec-
tively. The incremental cost-effectiveness of an extra pa-
tient achieving target on atorvastatin was $0.50 at 6
weeks, $0.42 at 12 weeks, $0.26 at 18 weeks and $0.51
at 24 weeks. CONCLUSION: Atorvastatin achieved a
greater percentage reduction in total cholesterol per mg
than simvastatin, and was equally well tolerated. While
drug costs for atorvastatin were slightly higher, overall
health care costs were lower than for simvastatin. Ator-
vastatin was more cost-effective than simvastatin in
achieving NHF targets. The incremental cost-effective-
ness of atorvastatin suggests additional patients can
achieve NHF targets relatively inexpensively.
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COST-EFFECTIVENESS OF LIPID LOWERING 
INTERVENTIONS IN A NATIVE AMERICAN 
CARDIOVASCULAR RISK 
REDUCTION PROGRAM
Kumar RN1, Borrego ME2, Gupchup GV2, Anderson JR2, 
Burden RW3, Phillips DL3
1University of Michigan, Ann Arbor, MI, USA; 2University of 
New Mexico, Albuquerque, NM, USA; 3Santa Fe Indian 
Hospital, Santa Fe, NM, USA
OBJECTIVES: To determine the cost-effectiveness (CE)
of managing patient low density lipoprotein-cholesterol
(LDL-C) levels with exercise plus nutritional therapy and
exercise plus nutritional plus pharmacotherapy from the
Indian Health Service perspective. METHODS: A retro-
spective database analysis was performed on data col-
lected from a pharmacist managed Cardiovascular Risk
Reduction Program (CVCRRP) from March 1997
through October 1999. Patients received exercise plus
nutritional therapy (Group 1) or exercise plus nutritional
plus pharmacotherapy (Group 2). Effectiveness measures
included unit and percent LDL-C reduction from initial
to last recorded visit. Costs (fixed plus variable) and re-
imbursements were determined in terms of 1999 dollar
values through clinic staff interviews and billing records
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